trending Market Intelligence /marketintelligence/en/news-insights/trending/oa2jm85z_f1s0gt6rm1jtw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Genome editing company LogicBio Therapeutics prices $70M IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Genome editing company LogicBio Therapeutics prices $70M IPO

LogicBio Therapeutics Inc. priced its IPO of 7 million common shares at $10 apiece to raise gross proceeds of about $70 million.

The genome editing company, which focuses on developing medicines to durably treat rare diseases in patients with significant unmet medical need, also plans to grant the underwriters an option to buy up to an additional 1,050,000 shares.

LogicBio's common stock is expected to start trading on the Nasdaq Global Market on Oct. 19 under the ticker symbol LOGC.

The offering is expected to close Oct. 23.

Jefferies, Barclays and William Blair are acting as joint book-running managers, while Chardan is acting as the lead manager for the IPO.